A landmark cluster-randomized trial in Kwale, Kenya, demonstrated that monthly mass administration of ivermectin to children aged 5–15 reduced new malaria infections by 26%, supplementing existing bed net interventions. The BOHEMIA project, funded by Unitaid, tested ivermectin’s efficacy amid rising insecticide resistance and behavioral shifts in mosquito vectors. Over 20,000 participants received treatments, underscoring ivermectin’s potential as a complementary malaria control tool in endemic regions.